NPS investors go long on positive Phase III short bowel results
This article was originally published in Scrip
Investors 31 January drove shares of NPS Pharmaceuticals as high as 34%, or $2.56, after the firm reported that its recombinant analogue of human glucagon-like peptide 2 (GLP-2), Gattex (teduglutide), reduced parenteral-nutrition (PN) dependence in adults with short-bowel syndrome (SBS) in a pivotal Phase III study – results analysts said almost assure the drug's US approval.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.